Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients
© 2023. The Author(s)..
BACKGROUND: Cysteinyl leukotrienes (CysLT) are potent inflammation-promoting mediators, but remain scarcely explored in COVID-19. We evaluated urinary CysLT (U-CysLT) relationship with disease severity and their usefulness for prognostication in hospitalized COVID-19 patients. The impact on U-CysLT of veno-venous extracorporeal membrane oxygenation (VV-ECMO) and of comorbidities such as hypertension and obesity was also assessed.
METHODS: Blood and spot urine were collected in "severe" (n = 26), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) patients with COVID-19 at days 1-2 (admission), 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point. U-CysLT were measured by ELISA. Routine markers, prognostic scores and outcomes were also evaluated.
RESULTS: U-CysLT did not differ between groups at admission, but significantly increased along hospitalization only in critical groups, being markedly higher in VV-ECMO patients, especially in hypertensives. U-CysLT values during the first week were positively associated with ICU and total hospital length of stay in critical groups and showed acceptable area under curve (AUC) for prediction of 30-day mortality (AUC: 0.734, p = 0.001) among all patients.
CONCLUSIONS: U-CysLT increase during hospitalization in critical COVID-19 patients, especially in hypertensives on VV-ECMO. U-CysLT association with severe outcomes suggests their usefulness for prognostication and as therapeutic targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Inflammation research : official journal of the European Histamine Research Society ... [et al. - 72(2023), 3 vom: 25. März, Seite 475-491 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reina-Couto, Marta [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.03.2023 Date Revised 21.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00011-022-01682-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351284370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351284370 | ||
| 003 | DE-627 | ||
| 005 | 20231226051005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00011-022-01682-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351284370 | ||
| 035 | |a (NLM)36617343 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reina-Couto, Marta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of urinary cysteinyl leukotrienes as biomarkers of severity and putative therapeutic targets in COVID-19 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2023 | ||
| 500 | |a Date Revised 21.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Cysteinyl leukotrienes (CysLT) are potent inflammation-promoting mediators, but remain scarcely explored in COVID-19. We evaluated urinary CysLT (U-CysLT) relationship with disease severity and their usefulness for prognostication in hospitalized COVID-19 patients. The impact on U-CysLT of veno-venous extracorporeal membrane oxygenation (VV-ECMO) and of comorbidities such as hypertension and obesity was also assessed | ||
| 520 | |a METHODS: Blood and spot urine were collected in "severe" (n = 26), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) patients with COVID-19 at days 1-2 (admission), 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point. U-CysLT were measured by ELISA. Routine markers, prognostic scores and outcomes were also evaluated | ||
| 520 | |a RESULTS: U-CysLT did not differ between groups at admission, but significantly increased along hospitalization only in critical groups, being markedly higher in VV-ECMO patients, especially in hypertensives. U-CysLT values during the first week were positively associated with ICU and total hospital length of stay in critical groups and showed acceptable area under curve (AUC) for prediction of 30-day mortality (AUC: 0.734, p = 0.001) among all patients | ||
| 520 | |a CONCLUSIONS: U-CysLT increase during hospitalization in critical COVID-19 patients, especially in hypertensives on VV-ECMO. U-CysLT association with severe outcomes suggests their usefulness for prognostication and as therapeutic targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Comorbidities | |
| 650 | 4 | |a Disease severity | |
| 650 | 4 | |a Outcomes | |
| 650 | 4 | |a Urinary cysteinyl leukotrienes | |
| 650 | 4 | |a Veno-venous extracorporeal membrane oxygenation (VV-ECMO) | |
| 650 | 7 | |a cysteinyl-leukotriene |2 NLM | |
| 650 | 7 | |a Leukotrienes |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Cysteine |2 NLM | |
| 650 | 7 | |a K848JZ4886 |2 NLM | |
| 700 | 1 | |a Roboredo-Madeira, Mariana |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira-Terra, Patrícia |e verfasserin |4 aut | |
| 700 | 1 | |a Silva-Pereira, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira-Santos, Luísa |e verfasserin |4 aut | |
| 700 | 1 | |a Pinho, Dora |e verfasserin |4 aut | |
| 700 | 1 | |a Dias, Andreia |e verfasserin |4 aut | |
| 700 | 1 | |a Cordeiro, Gonçalo |e verfasserin |4 aut | |
| 700 | 1 | |a Dias, Cláudia Camila |e verfasserin |4 aut | |
| 700 | 1 | |a Sarmento, António |e verfasserin |4 aut | |
| 700 | 1 | |a Tavares, Margarida |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, João T |e verfasserin |4 aut | |
| 700 | 1 | |a Roncon-Albuquerque, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, José-Artur |e verfasserin |4 aut | |
| 700 | 1 | |a Albino-Teixeira, António |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, Teresa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammation research : official journal of the European Histamine Research Society ... [et al. |d 1997 |g 72(2023), 3 vom: 25. März, Seite 475-491 |w (DE-627)NLM075208601 |x 1420-908X |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2023 |g number:3 |g day:25 |g month:03 |g pages:475-491 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00011-022-01682-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2023 |e 3 |b 25 |c 03 |h 475-491 | ||